A meta-analysis published in March pooled eleven randomized trials covering 6,139 people with obstructive sleep apnea and asked whether treating it with CPAP reduces cardiovascular events. Across everyone randomized, the answer was no: the relative risk for major adverse cardiovascular events was 1.00, with no reduction in death or stroke either. Among the subgroup who actually used the machine at least four hours a night, events fell by 29 percent and cardiovascular deaths by nearly two thirds.

Those two sentences describe the same trials, and the distance between them is the whole story. It is also the kind of finding that gets quoted selectively in both directions.

From the Lab to the Ledger

Obstructive sleep apnea is a mechanical problem. During sleep the soft tissue at the back of the throat collapses, airflow stops for seconds at a time, oxygen falls, and the brain briefly rouses to reopen the airway. Repeated hundreds of times a night, this produces surges of stress hormones, spikes in blood pressure, and fragmented sleep. The mechanism through which that would damage the heart and blood vessels over years is not speculative.

CPAP holds the airway open with a stream of pressurized air. It works, in the sense that it abolishes the events and restores oxygen levels, which is why it remains the standard treatment for moderate and severe disease. The problem the trials ran into is that people take the mask off. Average use in the large cardiovascular outcome trials ran at roughly three hours a night, well under the time most people spend asleep, so a treatment capable of working was measured in people receiving it for part of the night.

This is where the analysis needs care, and where a lot of coverage goes wrong. The four-hour subgroup was not randomized. People who tolerate CPAP differ from people who abandon it in ways that also predict cardiovascular outcomes: they tend to be more symptomatic, more adherent to everything else, and often healthier to begin with. The adherent-user result is consistent with CPAP working, and it is not proof, because the comparison is no longer a fair one. An intention-to-treat null and a per-protocol benefit is the classic signature of a treatment undermined by adherence, and it is also the classic signature of a treatment that does nothing while healthy people self-select into using it.

The population question sits underneath all of it. Most trials enrolled people who were not sleepy during the day, because sleepy patients cannot ethically be randomized to no treatment. Daytime sleepiness is the symptom CPAP relieves most reliably, so the trials systematically excluded the people who benefit most obviously.

Bio-Pipeline Ledger

CPAP for moderate to severe obstructive sleep apnea with daytime symptoms: established and effective for sleepiness, quality of life, and blood pressure. This indication does not depend on the cardiovascular question.

CPAP as cardiovascular prevention in people without symptoms: not demonstrated in randomized trials, with a favourable but non-randomized signal in those who use it consistently.

Home sleep apnea testing: validated for adults with a high pretest probability of moderate to severe disease, far cheaper and easier than a laboratory study, and prone to underestimating severity. A negative home test in someone with strong symptoms usually still warrants a laboratory study.

Mandibular advancement devices fitted by a dentist: an established alternative for mild to moderate disease, less effective per hour but often worn for more hours, which can close much of the gap.

Positional therapy and weight management: genuinely effective in selected people, particularly when events cluster while sleeping on the back.

Consumer wearables reporting an apnea estimate: useful as a prompt to get tested, not a diagnosis, and not a basis for treatment.

The Clinical Reality Check

What is established is that CPAP fixes the breathing, relieves daytime sleepiness, and lowers blood pressure modestly. Those are worthwhile on their own, and they are why the treatment exists.

What remains unsettled is whether it prevents heart attacks and strokes. The honest reading of the trial evidence is that the question has not been answered, because the trials could not get people to wear the device long enough to answer it. Both the confident claim that CPAP protects the heart and the confident claim that it does not are running past the data.

The useful consequence is about tolerance rather than motivation. If the mask is uncomfortable, that is a clinical problem with solutions, not a personal failing: mask style, humidification, pressure settings and ramp features all change tolerability, and a dental device is a legitimate alternative rather than a consolation prize. Loud snoring with witnessed pauses, morning headaches or unrefreshing sleep are worth raising with a physician, and testing is easier than it was. The evidence on whether the machine protects the heart is genuinely unresolved. The evidence on whether it makes people feel better is not.